vs
邦吉（BG）与MEDIFAST INC（MED）财务数据对比。点击上方公司名可切换其他公司
邦吉的季度营收约是MEDIFAST INC的65.1倍（$4.9B vs $75.1M）。邦吉同比增速更快（22.2% vs -36.9%）。邦吉自由现金流更多（$809.0M vs $-6.6M）。过去两年邦吉的营收复合增速更高（11.3% vs -34.4%）
邦吉（Bunge Global）是全球知名的农业与食品企业，注册地位于瑞士日内瓦，总部设在美国密苏里州圣路易斯市，业务覆盖农产品生产、加工、贸易及食品供应链服务等多个领域，在全球农业产业中拥有较高的市场地位。
迈德福斯特是一家总部位于美国马里兰州巴尔的摩的营养减重企业，该公司研发、分销并销售减重及健康相关产品，销售渠道涵盖官方网站、多层次营销、电话销售以及品牌加盟减重诊所。
BG vs MED — 直观对比
营收规模更大
BG
是对方的65.1倍
$75.1M
营收增速更快
BG
高出59.1%
-36.9%
自由现金流更多
BG
多$815.6M
$-6.6M
两年增速更快
BG
近两年复合增速
-34.4%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $4.9B | $75.1M |
| 净利润 | $95.0M | — |
| 毛利率 | 20.7% | 69.4% |
| 营业利润率 | 1.8% | -10.4% |
| 净利率 | 1.9% | — |
| 营收同比 | 22.2% | -36.9% |
| 净利润同比 | -84.2% | — |
| 每股收益（稀释后） | $-0.02 | $-1.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BGMED
| Q4 25 | $4.9B | $75.1M | ||
| Q3 25 | $4.4B | $89.4M | ||
| Q2 25 | $4.0B | $105.6M | ||
| Q1 25 | $3.7B | $115.7M | ||
| Q4 24 | $4.0B | $119.0M | ||
| Q3 24 | $3.9B | $140.2M | ||
| Q2 24 | $3.7B | $168.6M | ||
| Q1 24 | $3.9B | $174.7M |
净利润BGMED
| Q4 25 | $95.0M | — | ||
| Q3 25 | $166.0M | $-2.3M | ||
| Q2 25 | $354.0M | $2.5M | ||
| Q1 25 | $201.0M | $-772.0K | ||
| Q4 24 | $602.0M | — | ||
| Q3 24 | $221.0M | $1.1M | ||
| Q2 24 | $70.0M | $-8.2M | ||
| Q1 24 | $244.0M | $8.3M |
毛利率BGMED
| Q4 25 | 20.7% | 69.4% | ||
| Q3 25 | 24.3% | 69.5% | ||
| Q2 25 | 18.4% | 72.6% | ||
| Q1 25 | 16.3% | 72.8% | ||
| Q4 24 | 27.0% | 74.1% | ||
| Q3 24 | 19.9% | 75.4% | ||
| Q2 24 | 17.8% | 73.2% | ||
| Q1 24 | 22.2% | 72.8% |
营业利润率BGMED
| Q4 25 | 1.8% | -10.4% | ||
| Q3 25 | 6.2% | -4.6% | ||
| Q2 25 | 12.3% | -1.0% | ||
| Q1 25 | 7.8% | -1.1% | ||
| Q4 24 | 18.3% | 0.6% | ||
| Q3 24 | 8.3% | 1.5% | ||
| Q2 24 | 2.8% | -4.7% | ||
| Q1 24 | 9.4% | 4.5% |
净利率BGMED
| Q4 25 | 1.9% | — | ||
| Q3 25 | 3.8% | -2.5% | ||
| Q2 25 | 8.8% | 2.3% | ||
| Q1 25 | 5.5% | -0.7% | ||
| Q4 24 | 15.0% | — | ||
| Q3 24 | 5.7% | 0.8% | ||
| Q2 24 | 1.9% | -4.8% | ||
| Q1 24 | 6.2% | 4.8% |
每股收益（稀释后）BGMED
| Q4 25 | $-0.02 | $-1.64 | ||
| Q3 25 | $0.84 | $-0.21 | ||
| Q2 25 | $2.61 | $0.22 | ||
| Q1 25 | $1.48 | $-0.07 | ||
| Q4 24 | $4.27 | $0.08 | ||
| Q3 24 | $1.56 | $0.10 | ||
| Q2 24 | $0.48 | $-0.75 | ||
| Q1 24 | $1.68 | $0.76 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $2.0B | $167.3M |
| 总债务越低越好 | $10.2B | — |
| 股东权益账面价值 | $15.9B | $198.9M |
| 总资产 | $44.5B | $248.0M |
| 负债/权益比越低杠杆越低 | 0.64× | — |
8季度趋势，按日历期对齐
现金及短期投资BGMED
| Q4 25 | $2.0B | $167.3M | ||
| Q3 25 | $3.2B | $173.5M | ||
| Q2 25 | $7.1B | $162.7M | ||
| Q1 25 | $3.9B | $164.6M | ||
| Q4 24 | $3.8B | $162.3M | ||
| Q3 24 | $3.0B | $170.0M | ||
| Q2 24 | $1.3B | $163.5M | ||
| Q1 24 | $3.1B | $156.4M |
总债务BGMED
| Q4 25 | $10.2B | — | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $7.7B | — | ||
| Q1 25 | $5.4B | — | ||
| Q4 24 | $5.4B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $4.1B | — | ||
| Q1 24 | $4.1B | — |
股东权益BGMED
| Q4 25 | $15.9B | $198.9M | ||
| Q3 25 | $15.8B | $214.7M | ||
| Q2 25 | $10.9B | $216.0M | ||
| Q1 25 | $10.6B | $211.0M | ||
| Q4 24 | $9.9B | $210.1M | ||
| Q3 24 | $10.1B | $207.3M | ||
| Q2 24 | $10.0B | $205.3M | ||
| Q1 24 | $10.6B | $211.0M |
总资产BGMED
| Q4 25 | $44.5B | $248.0M | ||
| Q3 25 | $46.3B | $268.2M | ||
| Q2 25 | $31.2B | $269.3M | ||
| Q1 25 | $26.7B | $280.0M | ||
| Q4 24 | $24.9B | $284.2M | ||
| Q3 24 | $25.3B | $291.2M | ||
| Q2 24 | $24.4B | $293.5M | ||
| Q1 24 | $25.8B | $302.8M |
负债/权益比BGMED
| Q4 25 | 0.64× | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.51× | — | ||
| Q4 24 | 0.54× | — | ||
| Q3 24 | 0.54× | — | ||
| Q2 24 | 0.41× | — | ||
| Q1 24 | 0.39× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.3B | $-5.3M |
| 自由现金流经营现金流 - 资本支出 | $809.0M | $-6.6M |
| 自由现金流率自由现金流/营收 | 16.6% | -8.8% |
| 资本支出强度资本支出/营收 | 11.0% | 1.8% |
| 现金转化率经营现金流/净利润 | 14.18× | — |
| 过去12个月自由现金流最近4个季度 | $-879.0M | $1.2M |
8季度趋势，按日历期对齐
经营现金流BGMED
| Q4 25 | $1.3B | $-5.3M | ||
| Q3 25 | $854.0M | $12.1M | ||
| Q2 25 | $-1.1B | $-3.4M | ||
| Q1 25 | $-285.0M | $3.4M | ||
| Q4 24 | $1.1B | $-4.9M | ||
| Q3 24 | $1.3B | $9.1M | ||
| Q2 24 | $-1.5B | $13.1M | ||
| Q1 24 | $994.0M | $7.3M |
自由现金流BGMED
| Q4 25 | $809.0M | $-6.6M | ||
| Q3 25 | $385.0M | $10.8M | ||
| Q2 25 | $-1.5B | $-4.8M | ||
| Q1 25 | $-595.0M | $1.9M | ||
| Q4 24 | $564.0M | $-7.2M | ||
| Q3 24 | $973.0M | $7.7M | ||
| Q2 24 | $-1.8B | $11.1M | ||
| Q1 24 | $758.0M | $5.4M |
自由现金流率BGMED
| Q4 25 | 16.6% | -8.8% | ||
| Q3 25 | 8.8% | 12.0% | ||
| Q2 25 | -36.8% | -4.5% | ||
| Q1 25 | -16.2% | 1.6% | ||
| Q4 24 | 14.1% | -6.1% | ||
| Q3 24 | 25.1% | 5.5% | ||
| Q2 24 | -47.4% | 6.6% | ||
| Q1 24 | 19.2% | 3.1% |
资本支出强度BGMED
| Q4 25 | 11.0% | 1.8% | ||
| Q3 25 | 10.7% | 1.5% | ||
| Q2 25 | 10.1% | 1.3% | ||
| Q1 25 | 8.5% | 1.3% | ||
| Q4 24 | 12.2% | 1.9% | ||
| Q3 24 | 9.1% | 1.0% | ||
| Q2 24 | 8.0% | 1.1% | ||
| Q1 24 | 6.0% | 1.1% |
现金转化率BGMED
| Q4 25 | 14.18× | — | ||
| Q3 25 | 5.14× | — | ||
| Q2 25 | -3.03× | -1.36× | ||
| Q1 25 | -1.42× | — | ||
| Q4 24 | 1.75× | — | ||
| Q3 24 | 6.00× | 8.04× | ||
| Q2 24 | -21.06× | — | ||
| Q1 24 | 4.07× | 0.88× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BG
| Other Oilseeds Processing And Refining | $4.6B | 95% |
| Other | $251.0M | 5% |
| Other Products | $3.0M | 0% |
MED
暂无分部数据
